22 December 2025VideosAmericasMicheal Hebert, Greenberg Traurig | Chuck Sholtz, Verdiva Bio | Josh Mack, Halozyme | Lawrence Rozsnyai, Metsera

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
19 February 2026   An EPO appeals board has denied Boston Scientific’s bid to revoke St Jude Medical’s transcatheter aortic valve replacement (TAVR) patent, but declined to hand a complete victory to the patent owner.
Americas
13 February 2026   This year’s featured firms and individuals ranked by sister title WIPR, include those instructed on the biggest tech and life sciences cases, as well as the strategists devising global AI patent portfolios.
Americas
10 February 2026   Telehealth platform faces legal action from the Danish pharma giant, as well as FDA pressure over GLP-1 drugs and a drop in shares after discontinuing new product.